27/03/2025
(2025年3月27日马来西亚吉隆坡讯) 𝐁𝐢𝐨𝐠𝐞𝐧𝐝 𝐒𝐝𝐧 𝐁𝐡𝐝 正式宣布获得爱膝康（𝐑𝐞𝐯𝐨𝐜𝐚𝐫𝐭）一次性软骨修补系统的马来西亚专利代理权，并成功取得马来西亚卫生部医疗器材准证（𝐌𝐃𝐀）。这一里程碑标志着马来西亚医疗科技领域的一大进步，预计在2025年中旬开始为马来西亚患者提供创新的膝盖软骨修复手术。
爱膝康一次性软骨修补系统是一项突破性的医疗技术，旨在为软骨损伤的患者提供一种全新的治疗选择。相较于传统的全膝关节置换手术（TKR），爱膝康通过微创手术或内窥镜手术，利用患者自身的软骨进行修复，帮助患者保留原有膝盖或延迟更换人工膝盖的时间。该技术特别适用于患上退化性关节炎的年长者、因激烈运动导致软骨受伤的运动员，以及其他因软骨损伤而行动受限的患者。
✅媒体发布会详情
𝐁𝐢𝐨𝐠𝐞𝐧𝐝 𝐒𝐝𝐧 𝐁𝐡𝐝 于2025年3月27日（星期四）在吉隆坡PGRM举行媒体发布会，邀请了台湾博晟生医创办人兼董事长陈德礼医学博士亲临现场，分享爱膝康技术的创新之处及其在临床上的成功案例。陈德礼博士将深入讲解这项挑战传统的自体软骨细胞移植技术，并探讨其如何为患者带来更好的生活品质。
✅爱膝康技术的原理与优势
爱膝康一次性软骨修补系统的核心原理是利用患者自身关节中的少量软骨，经过特殊处理后注入可吸收性植入物，再通过微创手术植入到关节损伤部位。随着自体软骨的逐渐生长，植入物会慢慢降解并被身体吸收。手术伤口仅4至5公分，甚至更小，且无需取硬骨，大幅减少术后疼痛。手术时间短，通常在一小时内完成，显著降低了住院成本。
此外，爱膝康技术搭配创新的载体设计，能够修复更大面积的软骨损伤。截至2025年1月，爱膝康已在台湾成功应用于超过600名患者，涵盖膝关节、髋关节、踝关节、肘关节和肩关节等多个大关节。患者年龄介于11岁至85岁之间，其中20%的患者被诊断为退化性关节炎。在台湾，已有74家医院和130位骨科医师使用过爱膝康技术，单个关节最多使用九个载体，每个载体可修复1.4平方公分的软骨损伤。
✅未来展望
𝐁𝐢𝐨𝐠𝐞𝐧𝐝 𝐒𝐝𝐧 𝐁𝐡𝐝 期待通过引入爱膝康技术，为马来西亚患者提供更先进、更有效的软骨修复解决方案。公司相信，这项技术将为患者带来新的希望，帮助他们恢复行动能力，提升生活质量。
✅欢迎医生及合作伙伴洽询
如需了解更多详情请联系：
📞 Alan：016 217 8688
📞Brian：012 333 6676
📞Ted：018 321 9129
(Kuala Lumpur, Malaysia, March 27, 2025) 𝗕𝗶𝗼𝗴𝗲𝗻𝗱 𝗦𝗱𝗻 𝗕𝗵𝗱 officially announces that it has obtained the exclusive patent agency rights for the 𝗥𝗲𝘃𝗼𝗰𝗮𝗿𝘁 One-Time Cartilage Repair System in Malaysia and has successfully acquired the Medical Device Authority (MDA) certification from the Malaysian Ministry of Health. This milestone marks a significant advancement in Malaysia's medical technology sector, with plans to provide innovative knee cartilage repair surgery to Malaysian patients starting in mid-2025.
✅The 𝗥𝗲𝘃𝗼𝗰𝗮𝗿𝘁 One-Time Cartilage Repair System is a groundbreaking medical technology designed to offer a new treatment option for patients suffering from cartilage damage. Compared to traditional total knee replacement (TKR) surgery, 𝗥𝗲𝘃𝗼𝗰𝗮𝗿𝘁 utilizes minimally invasive or arthroscopic procedures to repair cartilage using the patient's own cartilage, helping them retain their natural knee or delay the need for artificial knee replacement. This technology is particularly suitable for elderly patients with degenerative arthritis, athletes who have sustained cartilage injuries from intense physical activities, and other individuals with mobility limitations due to cartilage damage.
✅𝗕𝗶𝗼𝗴𝗲𝗻𝗱 𝗦𝗱𝗻 𝗕𝗵𝗱 hold a media conference on Thursday, March 27, 2025, at PGRM in Kuala Lumpur. The event will feature Dr. Te-Li Chen, the founder and chairman of BioGend Therapeutics Co Ltd, who will personally attend to share insights on the innovation behind the Revocart technology and its clinical success cases. Dr. Chen will provide an in-depth discussion on how this technology challenges traditional autologous cartilage cell transplantation techniques and explores its potential to enhance patients' quality of life.
✅Principles and Advantages of 𝗥𝗲𝘃𝗼𝗰𝗮𝗿𝘁 Technology The core principle of the 𝗥𝗲𝘃𝗼𝗰𝗮𝗿𝘁 One-Time Cartilage Repair System involves harvesting a small amount of cartilage from the patient’s own joint, processing it through a specialized method, and injecting it into a bioabsorbable implant. This implant is then placed into the damaged cartilage area via a minimally invasive procedure. As the autologous cartilage gradually regenerates, the implant degrades and is absorbed by the body. The surgical incision is only 4 to 5 cm, sometimes even smaller, and does not require hard bone extraction, significantly reducing postoperative pain. The procedure is short, typically completed within an hour, which greatly lowers hospitalization costs.
Additionally, 𝗥𝗲𝘃𝗼𝗰𝗮𝗿𝘁 technology, with its innovative carrier design, can repair larger areas of cartilage damage. As of January 2025, 𝗥𝗲𝘃𝗼𝗰𝗮𝗿𝘁 has been successfully applied to over 600 patients in Taiwan, covering major joints such as the knee, hip, ankle, elbow, and shoulder. Patients range from 11 to 85 years old, with 20% diagnosed with degenerative arthritis. In Taiwan, 74 hospitals and 130 orthopedic surgeons have adopted the 𝗥𝗲𝘃𝗼𝗰𝗮𝗿𝘁 technology. A single joint can utilize up to nine carriers, each capable of repairing 1.4 square centimeters of cartilage damage.
✅Future Prospects 𝗕𝗶𝗼𝗴𝗲𝗻𝗱 𝗦𝗱𝗻 𝗕𝗵𝗱 aims to introduce 𝗥𝗲𝘃𝗼𝗰𝗮𝗿𝘁 technology to provide Malaysian patients with a more advanced and effective cartilage repair solution. The company believes that this technology will bring new hope to patients, helping them regain mobility and improve their quality of life.
✅Welcome Doctors and Partners for Inquiries , please contact: 📞 Alan: 016 217 8688 📞 Brian: 012 333 6676 📞 Ted: 018 321 9129
